Skip to main content
Premium Trial:

Request an Annual Quote

Ariosa, LabCorp Partner to Make T21 Test Available

NEW YORK (GenomeWeb News) – Ariosa Diagnostics today announced a partnership with Laboratory Corporation of America and Integrated Genetics to make its T21 test available in the US and Canada.

Integrated Genetics is a member of LabCorp's Specialty Testing Group. Financial and other terms of the deal were not disclosed.

Ariosa's test, called the Harmony Prenatal Test, will be offered through LabCorp and its more-than-1,000 patient service centers. The test is being made available at select locations and will be broadly launched next month, Ariosa said.

The test uses a maternal blood draw and detects common fetal trisomies, such as Trisomy 21. Ariosa CEO Ken Song told GenomeWeb Daily News last month that the test is for the detection of T18, as well as T21, and upon its broad launch will also detect for T13.

Harmony Prenatal is available for women at least 10 weeks into their pregnancy with a single fetus conceived without the use of an egg donor.

"With enhanced test performance and simplicity, the Harmony Prenatal Test can be reliably incorporated into the management of pregnancies," Song said in a statement.

Ariosa is the third firm to launch a non-invasive fetal aneuploidy test since late 2011, when Sequenom launched its MaterniT21 Plus test for T21, 18, and 13. Verinata Health launched its test called verifi in March.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more